Unknown

Dataset Information

Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine.


ABSTRACT:

Background and aim

To demonstrate the use of a standard dose of ledipasvir (LDV) and sofosbuvir (SOF), with or without ribavirin, to treat hepatitis C and hepatitis C/HIV co-infection in Ukraine.

Methods

Eligible HCV viraemic adults from two clinics in Kyiv were treated with LDV/SOF with or without weight-based ribavirin for 12 weeks. Clinical assessments were performed at screening and at week 24, and as needed; treatment was dispensed every 4 weeks. The primary outcome was sustained virologic response (SVR) 12 weeks after treatment, with analysis by intention to treat. Cost per patient was estimated in USD (2018) over the 24-week period.

Results

Of 868 patients included in the study and initiated on therapy, 482 (55.5%) were co-infected with HIV. The common genotype

SUBMITTER: Antoniak S 

PROVIDER: S-EPMC9730727 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature